Pathophysiology of Erectile Dysfunction: Difference between revisions
Urology4all (talk | contribs) |
Urology4all (talk | contribs) |
||
| Line 53: | Line 53: | ||
*# '''<span style="color:#ff0000">Diuretics</span>''' | *# '''<span style="color:#ff0000">Diuretics</span>''' | ||
*#* '''<span style="color:#ff0000">Spironolactone</span>''' is a nonselective mineralocorticoid receptor antagonist with moderate affinity for progesterone and androgen receptors. The latter property increases the likelihood of endocrine side effects, including loss of libido, gynecomastia, and impotence | *#* '''<span style="color:#ff0000">Spironolactone</span>''' is a nonselective mineralocorticoid receptor antagonist with moderate affinity for progesterone and androgen receptors. The latter property increases the likelihood of endocrine side effects, including loss of libido, gynecomastia, and impotence | ||
*#*'''Thiazides (e.g. hydrochlorothiazide)''' | |||
* '''<span style="color:#ff0000">Not associated with ED</span>''' | * '''<span style="color:#ff0000">Not associated with ED</span>''' | ||
*# '''<span style="color:#ff0000">ACE-inhibitors</span>''' | *# '''<span style="color:#ff0000">ACE-inhibitors</span>''' | ||